Virttu Biologics Company

Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer. Virttu Biologics Limited is a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc. Virttu has pioneered the development of oncolytic viruses for treating cancer. Although viruses naturally kill the cells they infect, weakened viruses have been used in medicine for centuries as vaccinations against the infectious diseases they cause. Scientists at Virttu have reprogrammed this ability in a common human virus so that it targets and kills only cancer cells (oncolysis), leaving normal cells unharmed.
Technology: Cell Therapies
Industry: Personalized Medicine
Headquarters: Leeds, Leeds, United Kingdom
Founded Date: 1999
Employees Number: Undisclosed
Funding Status: M&A

Visit Website
admin@virttu.com
Register and Claim Ownership